The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.
To assess the effect of Ocoxin-Viusid on the quality of life of patients with advanced pancreatic adenocarcinoma.
To evaluate the effect of Ocoxin-Viusid on the quality of life of patients. To evaluate the influence of Ocoxin-Viusid on tolerance to onco-specific therapy.
Identify the changes that occur in the nutritional status of patients receiving the supplement.
To evaluate the toxicity of Ocoxin-Viusid in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.
| Condition | Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases |
|---|---|
| Treatment | Ocoxin-Viusid® |
| Clinical Study Identifier | NCT03717298 |
| Sponsor | Catalysis SL |
| Last Modified on | 19 August 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.